C07D 215/14
Radicals substituted by oxygen atoms
C07D215/14 (Radicals substituted by oxygen atoms) appears on 860 US grants and 728 published applications in this corpus.
Search patents in C07D- Granted patents
- 860
- Published applications
- 728
- Assignees
- 461
- Inventors
- 2,777
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 4 | 0 |
| 1978 | 5 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 5 | 0 |
| 1986 | 8 | 0 |
| 1987 | 8 | 0 |
| 1988 | 11 | 0 |
| 1989 | 8 | 0 |
| 1990 | 21 | 0 |
| 1991 | 20 | 0 |
| 1992 | 25 | 0 |
| 1993 | 32 | 0 |
| 1994 | 23 | 0 |
| 1995 | 20 | 0 |
| 1996 | 15 | 0 |
| 1997 | 22 | 0 |
| 1998 | 32 | 0 |
| 1999 | 14 | 0 |
| 2000 | 21 | 0 |
| 2001 | 21 | 3 |
| 2002 | 27 | 24 |
| 2003 | 23 | 24 |
| 2004 | 15 | 41 |
| 2005 | 16 | 33 |
| 2006 | 22 | 39 |
| 2007 | 13 | 22 |
| 2008 | 17 | 19 |
| 2009 | 22 | 30 |
| 2010 | 12 | 34 |
| 2011 | 29 | 33 |
| 2012 | 13 | 27 |
| 2013 | 39 | 38 |
| 2014 | 34 | 49 |
| 2015 | 36 | 33 |
| 2016 | 25 | 39 |
| 2017 | 37 | 29 |
| 2018 | 23 | 26 |
| 2019 | 25 | 32 |
| 2020 | 19 | 31 |
| 2021 | 30 | 35 |
| 2022 | 14 | 26 |
| 2023 | 11 | 20 |
| 2024 | 13 | 17 |
| 2025 | 15 | 18 |
| 2026 | 3 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TEAD inhibitors and uses thereof16 Jun 2026US 12,655,150 B2Cedilla Therapeutics, Inc.
- Tetrahydroquinoline derivative and medicinal use thereof10 Mar 2026US 12,570,639 B2Toray Industries, Inc.
- Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide20 Jan 2026US 12,527,783 B2Bristol-Myers Squibb Company
- Hepatitis B antiviral agents16 Dec 2025US 12,496,282 B2Enanta Pharmaceuticals, Inc.
- Fluorescent probe, preparation method therefor and use thereof9 Dec 2025US 12,492,337 B2Fluorescence Diagnosis (Shanghai) Biotech Company
- Novel mitofusin inhibitors17 Sep 2026US 2026/0274810 A1Albert Einstein College of Medicine
- Methods and materials for increasing level of phosphorylated ampk protein21 May 2026US 2026/0138955 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Acetyl-coa carboxylase modulators23 Apr 2026US 2026/0109673 A1Monsanto Technology LLC
- Stilbene derivatives as well as preparation method therefor and use thereof2 Apr 2026US 2026/0091027 A1Thederma Shanghai Co., Ltd.
- Inhibitors of akr1c3 and methods of use5 Feb 2026US 2026/0035340 A1Board of Regents of the University of Nebraska
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity158US 5,023,341 AAllergan, Inc. · 1991